Insider Selling: National Research Co. (NASDAQ:NRC) Director Sells 6,989 Shares of Stock

National Research Co. (NASDAQ:NRC) Director Donald M. Berwick sold 6,989 shares of National Research stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $62.04, for a total transaction of $433,597.56.

Shares of NASDAQ:NRC traded up $0.35 on Friday, reaching $58.18. The company’s stock had a trading volume of 31,809 shares, compared to its average volume of 79,313. The stock’s 50-day moving average is $61.39 and its two-hundred day moving average is $41.10. National Research Co. has a 52-week low of $35.65 and a 52-week high of $68.86. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.62 and a quick ratio of 0.62. The stock has a market capitalization of $1.45 billion, a P/E ratio of 55.94 and a beta of 0.77.

National Research (NASDAQ:NRC) last announced its earnings results on Tuesday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $31.41 million during the quarter, compared to analysts’ expectations of $30.26 million. National Research had a net margin of 24.59% and a return on equity of 124.11%.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Monday, September 30th will be issued a dividend of $0.19 per share. The ex-dividend date is Friday, September 27th. This represents a $0.76 annualized dividend and a yield of 1.31%. National Research’s dividend payout ratio is currently 73.08%.

A number of hedge funds and other institutional investors have recently bought and sold shares of NRC. Vanguard Group Inc. raised its holdings in National Research by 10.3% during the second quarter. Vanguard Group Inc. now owns 562,951 shares of the company’s stock worth $32,421,000 after purchasing an additional 52,656 shares in the last quarter. Nuveen Asset Management LLC acquired a new position in National Research during the second quarter worth about $2,920,000. BlackRock Inc. grew its position in National Research by 7.5% during the second quarter. BlackRock Inc. now owns 709,948 shares of the company’s stock worth $40,885,000 after buying an additional 49,361 shares during the period. Renaissance Technologies LLC grew its position in National Research by 4.3% during the second quarter. Renaissance Technologies LLC now owns 513,800 shares of the company’s stock worth $29,590,000 after buying an additional 21,100 shares during the period. Finally, Isthmus Partners LLC grew its position in National Research by 98.4% during the second quarter. Isthmus Partners LLC now owns 31,925 shares of the company’s stock worth $1,839,000 after buying an additional 15,830 shares during the period. 36.03% of the stock is owned by hedge funds and other institutional investors.

Separately, ValuEngine cut shares of National Research from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Recommended Story: What are the benefits of buying treasury bonds?

Insider Buying and Selling by Quarter for National Research (NASDAQ:NRC)

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with's FREE daily email newsletter.